New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Friday, November 13, 2026

Back to the front page

From X

@calvinblissett

Calvin Blissett on X

$ZIM @ZeeContrarian1 @Chuckyb22074706 @ROICRHODES @christankerfund @MarkGroskyEsq. How are we thinking about $HLAG circa ~600m incentive to close this thing before March record date (giving us Q4 26’ div and top up). Thoughts and why would be appreciated. @Chuckyb22074706 is the only one to really touch on this and has a good point about better directors potentially moving up the record date. @ZeeContrarian1 first love your content and evident clarity of thought, thank you! I feel like your thesis is bulletproof except for this risk? How do you think about it especially since if I’m not mistaken you haven’t really touched upon it.
@StableBread

Fajasy on X

Boost Run $BRUN granted 6.23M RSUs in Q3, 7.4% of its 84.2M shares outstanding, and will expense $103.4M for them over a weighted-average 3 years, a cost its adjusted EBITDA excludes. The 6.23M includes the 4.59M granted to the CFO, CTO, and COO on September 29, and the 10-Q doesn't name who got the other 1.64M. Q3's stock comp was only $0.25M, since most of the RSUs came on September 29. $BRUN's adjusted EBITDA adds stock comp back, so from Q4 it will exclude ~$8.6M/quarter of RSU expense on average, equal to 47.9% of Q3's $18.0M of adjusted EBITDA. And $BRUN's 2026 equity plan still has 2,986,298 shares left to grant, another 3.5% of the shares outstanding. The bear, base, and bull cases in my October 19 update counted 88.8M fully diluted shares, including only the executives' 4.59M RSUs. The full 6.23M takes the count to 90.4M, which trims each case's per-share value by 1.8%.

Investor Letters

All letters

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3.1B
Mispriced Assets 3 clicks

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

PTON $2.5B
TSOH Investment Research 3 clicks

Quick note on LSAK and GRPN

Lesaka expects its Bank Zero acquisition to close by end-January 2027, though it could still close this calendar year.

GRPN $513M
Mispriced Assets 5 clicks
VITL · long

Vital Farms INC

Vital Farms is a long idea after bird flu-driven egg supply losses coincided with a structural shift.

VITL $385M
Value Investors Club

Vicor Update, Part Two

Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…

VICR $7.6B
CV's Substack 5 clicks

LQDA: finer powder, higher doses

Liquidia’s Yutrepia sales reached $170.4 million in Q2 2026, while a patent ruling threatens its PH-ILD label but leaves PAH sales and a…

LQDA $5.2B
Trade Ideas Flow 5 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 84 of 289

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.